Richard John Mears

Title: The Innovations of Richard John Mears

Introduction

Richard John Mears is a notable inventor based in Abingdon, GB. He has made significant contributions to the field of biochemistry, particularly in the development of kinase inhibitors. His work has implications for the treatment and prevention of various human ailments.

Latest Patents

Mears holds a patent for "Hexahydropyrazinotriazinone derivatives as kinase inhibitors." This patent describes a series of 1,2,6,7,9,9a-hexahydropyrazino[1,2-d][1,2,4]triazin-4-one derivatives. These compounds are substituted in the 8-position by an optionally substituted fused bicyclic heteroaromatic group and in the 3-position by a range of functional groups. They are selective inhibitors of phosphatidylinositol-4-kinase IIIβ (PI4KIIIβ) activity. This innovation is beneficial in treating and preventing various human ailments, including inflammatory, autoimmune, and oncological disorders, as well as viral diseases, malaria, and organ and cell transplant rejection.

Career Highlights

Throughout his career, Richard John Mears has worked with prominent organizations such as UCB Biopharma and Katholieke Universiteit Leuven, also known as KU Leuven R&D. His expertise in biochemistry and pharmacology has allowed him to contribute to significant advancements in medical research.

Collaborations

Mears has collaborated with notable colleagues, including Helen Tracey Horsley and Judi Charlotte Neuss. These partnerships have furthered his research and development efforts in the field of kinase inhibitors.

Conclusion

Richard John Mears is a distinguished inventor whose work in kinase inhibitors has the potential to impact the treatment of various diseases. His contributions to biochemistry and collaborations with esteemed organizations highlight his importance in the field.